These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 36456600)
41. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502 [TBL] [Abstract][Full Text] [Related]
42. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. Hu J; Jo M; Cavenee WK; Furnari F; VandenBerg SR; Gonias SL Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15984-9. PubMed ID: 21896743 [TBL] [Abstract][Full Text] [Related]
43. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Tang CK; Gong XQ; Moscatello DK; Wong AJ; Lippman ME Cancer Res; 2000 Jun; 60(11):3081-7. PubMed ID: 10850460 [TBL] [Abstract][Full Text] [Related]
44. Cell line with endogenous EGFRvIII expression is a suitable model for research and drug development purposes. Stec WJ; Rosiak K; Siejka P; Peciak J; Popeda M; Banaszczyk M; Pawlowska R; Treda C; Hulas-Bigoszewska K; Piaskowski S; Stoczynska-Fidelus E; Rieske P Oncotarget; 2016 May; 7(22):31907-25. PubMed ID: 27004406 [TBL] [Abstract][Full Text] [Related]
45. Identification of a novel colon adenocarcinoma cell targeting peptide using phage display library biopanning. Bakhshinejad B; Sadeghizadeh M Biotechnol Appl Biochem; 2022 Dec; 69(6):2753-2765. PubMed ID: 35103339 [TBL] [Abstract][Full Text] [Related]
46. Generation of humanized single-chain fragment variable immunotherapeutic against EGFR variant III using baculovirus expression system and in vitro validation. Xavier S; Gopi Mohan C; Nair S; Menon KN; Vijayachandran LS Int J Biol Macromol; 2019 Mar; 124():17-24. PubMed ID: 30471391 [TBL] [Abstract][Full Text] [Related]
47. Development of an EGFRvIII specific recombinant antibody. Gupta P; Han SY; Holgado-Madruga M; Mitra SS; Li G; Nitta RT; Wong AJ BMC Biotechnol; 2010 Oct; 10():72. PubMed ID: 20925961 [TBL] [Abstract][Full Text] [Related]
48. Application of Next Generation Sequencing (NGS) in Phage Displayed Peptide Selection to Support the Identification of Arsenic-Binding Motifs. Braun R; Schönberger N; Vinke S; Lederer F; Kalinowski J; Pollmann K Viruses; 2020 Nov; 12(12):. PubMed ID: 33261041 [TBL] [Abstract][Full Text] [Related]
49. EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma. Li L; Puliyappadamba VT; Chakraborty S; Rehman A; Vemireddy V; Saha D; Souza RF; Hatanpaa KJ; Koduru P; Burma S; Boothman DA; Habib AA Oncogene; 2015 Jan; 34(1):129-134. PubMed ID: 24362532 [TBL] [Abstract][Full Text] [Related]
50. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Sampson JH; Aldape KD; Archer GE; Coan A; Desjardins A; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling R; Shi W; Vredenburgh JJ; Bigner DD; Heimberger AB Neuro Oncol; 2011 Mar; 13(3):324-33. PubMed ID: 21149254 [TBL] [Abstract][Full Text] [Related]
55. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Mukherjee B; McEllin B; Camacho CV; Tomimatsu N; Sirasanagandala S; Nannepaga S; Hatanpaa KJ; Mickey B; Madden C; Maher E; Boothman DA; Furnari F; Cavenee WK; Bachoo RM; Burma S Cancer Res; 2009 May; 69(10):4252-9. PubMed ID: 19435898 [TBL] [Abstract][Full Text] [Related]
56. Epidermal growth factor receptor variant III contributes to cancer stem cell phenotypes in invasive breast carcinoma. Del Vecchio CA; Jensen KC; Nitta RT; Shain AH; Giacomini CP; Wong AJ Cancer Res; 2012 May; 72(10):2657-71. PubMed ID: 22419663 [TBL] [Abstract][Full Text] [Related]
57. Bakas S; Akbari H; Pisapia J; Martinez-Lage M; Rozycki M; Rathore S; Dahmane N; O'Rourke DM; Davatzikos C Clin Cancer Res; 2017 Aug; 23(16):4724-4734. PubMed ID: 28428190 [No Abstract] [Full Text] [Related]
58. Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature. Jones KA; Gilder AS; Lam MS; Du N; Banki MA; Merati A; Pizzo DP; VandenBerg SR; Gonias SL Neuro Oncol; 2016 May; 18(5):667-78. PubMed ID: 26420897 [TBL] [Abstract][Full Text] [Related]
59. Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma. Katanasaka Y; Kodera Y; Kitamura Y; Morimoto T; Tamura T; Koizumi F Mol Cancer; 2013 Apr; 12():31. PubMed ID: 23617883 [TBL] [Abstract][Full Text] [Related]
60. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Feldkamp MM; Lala P; Lau N; Roncari L; Guha A Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]